iQnovate prepares for intended redomicile and NASDAQ listing
In yesterday’s market announcement, iQnovate Ltd (IQN) intends to redomicile in the US, in preparation for an intended listing on Nasdaq. The redomicile is being carried out via a scheme of arrangement between IQN and The iQ Group Global Inc (TIGG). “After seven years of significant growth in Australia, IQN has acquired, developed and de-risked […]
Chinese patent granted for the Biosensor platform
iQnovate Ltd (NSX:IQN) The executive management of iQnovate Ltd, on behalf of its subsidiary company Life Science Biosensor Diagnostics Pty Ltd (LSBD), is pleased to announce it has been granted a key patent for its biosensor platform in the People’s Republic of China. This will enable LSBD to enjoy patent protection in China until the […]
Saliva Glucose Biosensor and 3 new diagnostic test portfolios – market update
The executive management of iQnovate Ltd on behalf of its subsidiary company, Life Science Biosensor Diagnostics Pty Ltd, is pleased to provide the following update on the development program for the Saliva Glucose Biosensor and its broader Biosensor Platform – BioSensX, with the initiation of three new diagnostic test portfolios. Saliva Glucose Biosensor The Saliva […]
A spotlight on Biotech – Dr George Syrmalis speaks to Alan Kohler
Dr George Syrmalis, CEO and founder of The iQ Group Global was recently interviewed by Alan Kohler as part of the CEO Interview series on the investor subscription website, The Constant Investor. Dr Syrmalis discusses what people should consider when investing in biotech and the interview, in Alan’s own words, is ‘fascinating’ and ‘really worth […]